Drug intelligence / Profile preview

SPQ

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

SPQ is an enantiomer of primaquine, an antimalarial drug. It is currently under investigation in clinical trials to assess its comparative tolerability, metabolism, and pharmacokinetic behavior in healthy human volunteers and individuals with G6PD deficiency. Studies aim to evaluate its effects on hematological parameters, with a primary focus on its potential use in treating malaria.

Other names: primaquine enantiomer

Beyond the preview

Go deeper on SPQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPQ.

Explore the full profile